mofetil and glucocorticoids over cyclophosphamide or rituximab and glucocorticoids. While the comparative efficacy of methotrexate, azathioprine, mycophenolate mofetil, and rituximab is not well established, the use of methotrexate, azathioprine, or mycophenolate mofetil is favored, based on more experience with these agents in EGPA compared to rituximab. However, rituximab may be considered if other agents are not effective in controlling active, nonsevere disease, or if the patient has